Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sanofi Global Health

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

- PMLiVE

Genzyme on track for eliglustat filing in 2013

Says oral Gaucher disease drug as effective as its injectable Cerezyme

Sanofi’s Steve Oldfield to co-chair UK medicines access group

Takes over from UCB’s Matthew Speers in joint government/industry group

Sanofi reception

Sanofi predicts end of patent cliff in 2013

New launches to overcome generic competition

- PMLiVE

Sanofi backs SMS chemotherapy compliance programme

Prost8Care delivers timed text message encouragement to cancer patients

- PMLiVE

Sanofi launches voice-guided epinephrine auto-injector in US

Auvi-Q extends pharma company's interests in innovative devices

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

Sanofi reception

US approval for Sanofi’s Kynamro in genetic cholesterol disorder

Comes one month after drug was turned down in Europe due to safety concerns

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

Sanofi US joins NBA for diabetes awareness drive

Andre Iguodala, Danny Granger and Tamika Catchings sign up as ambassadors for Dribble to Stop Diabetes

Gary Nabel to lead Sanofi’s strategy council

Pharma firm’s chief scientific officer replaces Richard Klausner

Sanofi reception

Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links